307 related articles for article (PubMed ID: 16920030)
1. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.
Daniels TR; Delgado T; Helguera G; Penichet ML
Clin Immunol; 2006 Nov; 121(2):159-76. PubMed ID: 16920030
[TBL] [Abstract][Full Text] [Related]
2. The transferrin receptor and the targeted delivery of therapeutic agents against cancer.
Daniels TR; Bernabeu E; Rodríguez JA; Patel S; Kozman M; Chiappetta DA; Holler E; Ljubimova JY; Helguera G; Penichet ML
Biochim Biophys Acta; 2012 Mar; 1820(3):291-317. PubMed ID: 21851850
[TBL] [Abstract][Full Text] [Related]
3. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
Daniels TR; Delgado T; Rodriguez JA; Helguera G; Penichet ML
Clin Immunol; 2006 Nov; 121(2):144-58. PubMed ID: 16904380
[TBL] [Abstract][Full Text] [Related]
4. [Transferrin conjugates in the anticancer therapy].
Lubgan D; Marczak A; Distel L; Jóźwiak Z
Postepy Biochem; 2006; 52(1):72-9. PubMed ID: 16869304
[TBL] [Abstract][Full Text] [Related]
5. Transferrin-oligomers as potential carriers in anticancer drug delivery.
Lim CJ; Shen WC
Pharm Res; 2004 Nov; 21(11):1985-92. PubMed ID: 15587919
[TBL] [Abstract][Full Text] [Related]
6. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
7. Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin.
Luck AN; Mason AB
Adv Drug Deliv Rev; 2013 Jul; 65(8):1012-9. PubMed ID: 23183585
[TBL] [Abstract][Full Text] [Related]
8. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
9. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.
Tortorella S; Karagiannis TC
J Membr Biol; 2014 Apr; 247(4):291-307. PubMed ID: 24573305
[TBL] [Abstract][Full Text] [Related]
10. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
Ng PP; Dela Cruz JS; Sorour DN; Stinebaugh JM; Shin SU; Shin DS; Morrison SL; Penichet ML
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10706-11. PubMed ID: 12149472
[TBL] [Abstract][Full Text] [Related]
11. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
12. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer.
Anabousi S; Bakowsky U; Schneider M; Huwer H; Lehr CM; Ehrhardt C
Eur J Pharm Sci; 2006 Dec; 29(5):367-74. PubMed ID: 16952451
[TBL] [Abstract][Full Text] [Related]
14. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
Crépin R; Goenaga AL; Jullienne B; Bougherara H; Legay C; Benihoud K; Marks JD; Poul MA
Cancer Res; 2010 Jul; 70(13):5497-506. PubMed ID: 20530676
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.
Amreddy N; Muralidharan R; Babu A; Mehta M; Johnson EV; Zhao YD; Munshi A; Ramesh R
Int J Nanomedicine; 2015; 10():6773-88. PubMed ID: 26604751
[TBL] [Abstract][Full Text] [Related]
16. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
17. Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer.
Mojarad-Jabali S; Mahdinloo S; Farshbaf M; Sarfraz M; Fatahi Y; Atyabi F; Valizadeh H
Expert Opin Drug Deliv; 2022 Jun; 19(6):685-705. PubMed ID: 35698794
[TBL] [Abstract][Full Text] [Related]
18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
19. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
[TBL] [Abstract][Full Text] [Related]
20. The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems.
Tortorella S; Karagiannis TC
Curr Drug Deliv; 2014; 11(4):427-43. PubMed ID: 24387131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
